EP1577288A4 — Selective estrogen receptor modulators
Assigned to Eisai R&D Management Co Ltd · Expires 2008-02-27 · 18y expired
What this patent protects
Compounds represented by the general formula (I), salts thereof, and hydrates of both: (I) wherein T is a single bond, optionally substituted C1-4 alkylene, or the like; the symbols ˙˙˙˙˙˙ are each a single bond or a double bond; A is a single bond, a divalent group derived from …
USPTO Abstract
Compounds represented by the general formula (I), salts thereof, and hydrates of both: (I) wherein T is a single bond, optionally substituted C1-4 alkylene, or the like; the symbols ˙˙˙˙˙˙ are each a single bond or a double bond; A is a single bond, a divalent group derived from a 5- to 14-membered heterocycle which may be substituted, or the like; Y is a single bond or the like; Z is methylene or the like; G is phenylene optionally fused with a 5- or 6-membered ring which may have a heteroatom, or the like; Ra and Rb are each independently hydrogen or the like; W is a single bond or the like; R’ represents one to four independent hydrogen atoms or the like; and R” represents one to four independent hydrogen atoms or the like.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.